Understanding the biology in both tumor (site of efficacy) and normal (sites of potential dose limiting toxicity), & understanding how to tailor the linker to that biology
18 Jun 2025
Linker Design
- How do differences in the internalization pathway between tumor and normal cells contribute to the therapeutic margin of solid tumor targets?
- Why is studying the internalization pathway in vivo challenging, and what are the limitations of in vitro studies in this context?
- In what ways can variations in the internalization pathway, such as rate, destination, or interaction partners, be leveraged to enhance the therapeutic margin through linker design?
- Why is the linker often the last component of an ADC to be designed, and how do time constraints impact its optimization?
- How do the choice of antibody and payload influence the proper design of the linker in ADC development?
Industry Expert
